Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.
暂无分享，去创建一个
David Wholley | Anne Wallace | Michael Hogarth | Laura Esserman | Lajos Pusztai | Rita Nanda | Julie Lang | Olufunmilayo I Olopade | Brian Leyland-Jones | Alan Hu | David Dilts | Christopher Benz | Angela DeMichele | Donald A Berry | D. Berry | L. Esserman | A. Barker | O. Olopade | L. Pusztai | Minetta C. Liu | D. Yee | C. Benz | B. Leyland-Jones | M. Hogarth | H. Rugo | A. DeMichele | J. Boughey | R. Nanda | K. Albain | John W. Park | B. Parker | F. Symmans | D. Tripathy | D. Dilts | D. Northfelt | T. Haddad | P. Haluska | J. Perlmutter | D. Parkinson | M. Buxton | A. Chien | A. Wallace | H. Kaplan | A. Elias | J. Lang | Q. Khan | David Wholley | Debu Tripathy | Douglas Yee | Tufia Haddad | Kathy Albain | Anna Barker | Judy Boughey | Meredith Buxton | Amy Jo Chien | Anthony Elias | Paul Haluska | Nola Hytlon | Henry G Kaplan | Gary G Kelloff | Qamar Khan | Minetta Liu | Donald Northfelt | John Park | Barbara Parker | David Parkinson | Sonia Pearson-White | Jane Perlmutter | Fraser Symmans | Hope Rugo | Laura Van't Veer | S. Pearson-White | A. Hu | L. V. van’t Veer | Gary Kelloff | Nola Hytlon | A. J. Chien
[1] Michael D Fetters,et al. Achieving integration in mixed methods designs-principles and practices. , 2013, Health services research.
[2] Daniel F Hayes,et al. Defining the benefits of neoadjuvant chemotherapy for breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Neal J Meropol,et al. The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Janet Woodcock,et al. Accelerating identification and regulatory approval of investigational cancer drugs. , 2011, JAMA.
[5] S. Martino,et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.
[6] L. Esserman,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[7] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[9] C. Osborne,et al. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.